Papers/PMID:24484547
Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis.
Journal of translational medicine2014The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
L-ascorbic acid — decreases C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Ascorbic acid significantly reduced the proinflammatory biomarkers C-reactive protein and procalcitonin.”
Quoted verbatim from Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis.. - Study
- RCT
- Duration
- 4 days
- Dose
- 50 mg/kg/24 h or 200 mg/kg/24 h intravenously, infusions every six hours for four days
- Population
- 24 patients with severe sepsis in a medical intensive care unit; low-dose and high-dose ascorbic acid arms versus placebo (5% dextrose/water)
Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis.2014PMID:24484547Permalink